BODIPY 581/591 C11: Ratiometric Fluorescent Lipid Peroxidation Probe for Oxidative Stress Detection

Executive Summary: BODIPY 581/591 C11 (SKU C8003, APExBIO) is a cell-permeable, ratiometric fluorescent probe designed to detect lipid peroxidation and evaluate antioxidant capacity in live cells and biological membranes [product page]. Upon oxidation, its fluorescence emission shifts from red (591 nm) to green (510 nm), enabling quantitative assessment of oxidative stress [Zhang et al. 2025]. The probe is highly photostable, exhibits a high quantum yield, and is specific to oxygen radicals and peroxynitrite. It is widely used in studies of ferroptosis, cancer, and neurodegenerative disease models. Recent literature highlights its role in validating antioxidant interventions and dissecting lipid peroxidation pathways [Zhang et al. 2025].

Biological Rationale

Lipid peroxidation is a hallmark of oxidative stress and a driver of cell injury in numerous pathological conditions, including cancer and neurodegenerative diseases [Zhang et al. 2025]. Reactive oxygen species (ROS) attack polyunsaturated fatty acids (PUFAs) in membrane lipids, initiating chain reactions that disrupt membrane structure and function. Quantifying lipid peroxidation is critical for evaluating antioxidant defenses and understanding mechanisms of cell death, such as ferroptosis. Traditional methods, such as thiobarbituric acid reactive substances (TBARS) assays, lack spatial and kinetic resolution. Ratiometric fluorescent probes like BODIPY 581/591 C11 enable real-time, quantitative, and compartment-specific detection of lipid peroxidation in live cells and tissues [See also].

Mechanism of Action of BODIPY 581/591 C11

BODIPY 581/591 C11 (CAS 217075-36-0) comprises a lipophilic BODIPY fluorophore conjugated to a polyunsaturated butadienyl segment. In its reduced state, the probe displays red fluorescence (excitation/emission: 581/591 nm). Upon oxidation by specific ROS—most notably hydroxyl radicals and peroxynitrite—the polyunsaturated chain undergoes peroxidation, causing a pronounced spectral shift to green fluorescence (excitation/emission: 488/510 nm). This ratiometric shift enables direct quantification: the red/green fluorescence ratio in live-cell imaging or flow cytometry correlates with the degree of membrane lipid peroxidation. The probe is not responsive to superoxide, nitric oxide, or hydrogen peroxide, conferring high specificity [extended workflow discussion].

Evidence & Benchmarks

• BODIPY 581/591 C11 enables robust, real-time, ratiometric quantification of lipid peroxidation in live MC3T3-E1 cells under oxidative stress (Zhang et al. 2025, https://doi.org/10.2147/DDDT.S554610).
• The probe’s photostability and high quantum yield (~0.6) support quantitative imaging across repeated exposures (see APExBIO product data).
• The emission ratio (red/green) correlates linearly with lipid peroxidation levels induced by ferroptosis inducers and is reversible with antioxidants such as Vitamin K2 (Zhang et al. 2025, https://doi.org/10.2147/DDDT.S554610).
• No significant signal change occurs in the presence of superoxide, nitric oxide, or hydrogen peroxide, verifying ROS subtype selectivity (APExBIO datasheet, product page).
• Quantitative ratiometric detection is reproducible in both flow cytometry and confocal microscopy platforms (see workflow review).

Applications, Limits & Misconceptions

BODIPY 581/591 C11 is widely applied in:

• Monitoring lipid oxidative stress in live cell and tissue models.
• Evaluating antioxidant efficacy in vitro and ex vivo.
• Dissecting ferroptosis pathways in cancer and neurodegenerative disease research.
• Validating interventions targeting NRF2/FSP1 signaling for osteoblast protection (Zhang et al. 2025).

This article extends previous scenario-based guidance (e.g., BODIPY C11: Gold Standard for Antioxidant Capacity Evaluation) by providing detailed, evidence-backed boundaries for probe specificity and workflow integration.

Common Pitfalls or Misconceptions

• Not a generic ROS probe: The probe is unresponsive to superoxide, nitric oxide, and H₂O₂; it detects only lipid peroxidation resulting from specific oxygen radicals and peroxynitrite (APExBIO).
• Not suitable for long-term solution storage: Probe solutions are unstable; always prepare fresh aliquots to ensure signal fidelity (APExBIO).
• Does not measure protein or DNA oxidation: Signal is specific to lipid oxidation; other oxidative events are not detected (see Q&A workflow).
• Requires protection from light and moisture: Storage at -20°C in desiccated, dark conditions is mandatory for shelf life maintenance (APExBIO).

Workflow Integration & Parameters

BODIPY 581/591 C11 integrates into standard live-cell and membrane model assays. Key protocol parameters include:

• Reconstitution: Dissolve solid probe in DMSO to 1–10 mM; dilute to 1–5 μM for cell labeling (incubate 15–30 min at 37°C, protect from light).
• Imaging: Dual-channel acquisition (exc. 581/em. 591 nm; exc. 488/em. 510 nm) supports ratiometric quantitation.
• Controls: Use positive controls (e.g., ferroptosis inducers like erastin) and negative controls (antioxidants such as Vitamin K2) to calibrate signal window (Zhang et al. 2025).
• Data Analysis: Calculate the red/green emission ratio as a direct readout of lipid peroxidation status.
• Interlink: For advanced troubleshooting and reproducibility guidance, see scenario-driven Q&A workflows; this article provides updated, evidence-based protocol boundaries.

The C8003 kit from APExBIO is widely cited for robust and reproducible lipid peroxidation detection in research settings [product page].

Conclusion & Outlook

BODIPY 581/591 C11 is a validated, ratiometric fluorescent probe that enables precise, quantitative detection of lipid peroxidation and oxidative stress in biomedical research. Its specificity for oxygen radical-mediated lipid oxidation, photostability, and compatibility with standard imaging and flow cytometry platforms make it a gold standard for antioxidant capacity evaluation and related mechanistic studies. Ongoing research, including studies on NRF2/FSP1 signaling and ferroptosis, continues to expand its utility across disease models and therapeutic development [Zhang et al. 2025].